Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 35

1.

Metastatic Bulk Independently Predicts Outcomes for EGFR Precision Targeting in Colorectal Cancer.

Kratz JD, Uboha NV, Lubner SJ, Mulkerin DL, Clipson L, Yi Y, Yu M, Matkowskyj KA, LoConte NK, Deming DA.

J Natl Compr Canc Netw. 2018 Dec;16(12):1442-1450. doi: 10.6004/jnccn.2018.7074.

PMID:
30545991
2.

A phase 2 randomised study of veliparib plus FOLFIRI┬▒bevacizumab versus placebo plus FOLFIRI┬▒bevacizumab in metastatic colorectal cancer.

Gorbunova V, Beck JT, Hofheinz RD, Garcia-Alfonso P, Nechaeva M, Cubillo Gracian A, Mangel L, Elez Fernandez E, Deming DA, Ramanathan RK, Torres AH, Sullivan D, Luo Y, Berlin JD.

Br J Cancer. 2019 Jan;120(2):183-189. doi: 10.1038/s41416-018-0343-z. Epub 2018 Dec 11.

PMID:
30531832
3.

Activating Mutations in Pik3ca Contribute to Anal Carcinogenesis in the Presence or Absence of HPV-16 Oncogenes.

Shin MK, Payne S, Bilger A, Matkowskyj KA, Carchman E, Meyer DS, Bentires-Alj M, Deming DA, Lambert PF.

Clin Cancer Res. 2018 Dec 7. doi: 10.1158/1078-0432.CCR-18-2843. [Epub ahead of print]

PMID:
30530704
4.

MTORC1/2 Inhibition as a Therapeutic Strategy for PIK3CA Mutant Cancers.

Fricke SL, Payne SN, Favreau PF, Kratz JD, Pasch CA, Foley TM, Yueh AE, Van De Hey DR, Depke MG, Korkos DP, Sha GC, DeStefanis RA, Clipson L, Burkard ME, Lemmon KK, Parsons BM, Kenny PA, Matkowskyj KA, Newton MA, Skala MC, Deming DA.

Mol Cancer Ther. 2019 Feb;18(2):346-355. doi: 10.1158/1535-7163.MCT-18-0510. Epub 2018 Nov 13.

PMID:
30425131
5.

Molecular Evolution of a Glioblastoma Controlled With Tumor Treating Fields and Concomitant Temozolomide.

Robins HI, Nguyen HN, Field A, Howard S, Salamat S, Deming DA.

Front Oncol. 2018 Oct 15;8:451. doi: 10.3389/fonc.2018.00451. eCollection 2018.

6.

The conserved protective cyclic AMP-phosphodiesterase function PDE4B is expressed in the adenoma and adjacent normal colonic epithelium of mammals and silenced in colorectal cancer.

Pleiman JK, Irving AA, Wang Z, Toraason E, Clipson L, Dove WF, Deming DA, Newton MA.

PLoS Genet. 2018 Sep 6;14(9):e1007611. doi: 10.1371/journal.pgen.1007611. eCollection 2018 Sep.

7.

Tailoring the colorectal cancer disease assessment to the treatment strategy.

Deming DA.

Gut. 2018 Jun;67(6):996-997. doi: 10.1136/gutjnl-2017-315394. Epub 2017 Dec 21. No abstract available.

PMID:
29269439
8.

CT texture features of liver parenchyma for predicting development of metastatic disease and overall survival in patients with colorectal cancer.

Lee SJ, Zea R, Kim DH, Lubner MG, Deming DA, Pickhardt PJ.

Eur Radiol. 2018 Apr;28(4):1520-1528. doi: 10.1007/s00330-017-5111-6. Epub 2017 Nov 21.

PMID:
29164382
9.

A Blueprint to Advance Colorectal Cancer Immunotherapies.

Le DT, Hubbard-Lucey VM, Morse MA, Heery CR, Dwyer A, Marsilje TH, Brodsky AN, Chan E, Deming DA, Diaz LA Jr, Fridman WH, Goldberg RM, Hamilton SR, Housseau F, Jaffee EM, Kang SP, Krishnamurthi SS, Lieu CH, Messersmith W, Sears CL, Segal NH, Yang A, Moss RA, Cha E, O'Donnell-Tormey J, Roach N, Davis AQ, McAbee K, Worrall S, Benson AB.

Cancer Immunol Res. 2017 Nov;5(11):942-949. doi: 10.1158/2326-6066.CIR-17-0375. Epub 2017 Oct 16.

10.

Versican-Derived Matrikines Regulate Batf3-Dendritic Cell Differentiation and Promote T Cell Infiltration in Colorectal Cancer.

Hope C, Emmerich PB, Papadas A, Pagenkopf A, Matkowskyj KA, Van De Hey DR, Payne SN, Clipson L, Callander NS, Hematti P, Miyamoto S, Johnson MG, Deming DA, Asimakopoulos F.

J Immunol. 2017 Sep 1;199(5):1933-1941. doi: 10.4049/jimmunol.1700529. Epub 2017 Jul 28.

11.

Primary and acquired resistance to biologic therapies in gastrointestinal cancers.

Lubner SJ, Uboha NV, Deming DA.

J Gastrointest Oncol. 2017 Jun;8(3):499-512. doi: 10.21037/jgo.2017.01.16. Review.

12.

Safety and tolerability of veliparib combined with capecitabine plus radiotherapy in patients with locally advanced rectal cancer: a phase 1b study.

Czito BG, Deming DA, Jameson GS, Mulcahy MF, Vaghefi H, Dudley MW, Holen KD, DeLuca A, Mittapalli RK, Munasinghe W, He L, Zalcberg JR, Ngan SY, Komarnitsky P, Michael M.

Lancet Gastroenterol Hepatol. 2017 Jun;2(6):418-426. doi: 10.1016/S2468-1253(17)30012-2. Epub 2017 Mar 27.

PMID:
28497757
13.

Using cancer genomics to guide clinical decisions.

Burkard ME, Deming DA, Lauring J.

Cancer. 2017 Apr 15;123(8):1288-1291. doi: 10.1002/cncr.30640. Epub 2017 Mar 2. No abstract available.

14.

Dual PI3K/mTOR Inhibition in Colorectal Cancers with APC and PIK3CA Mutations.

Foley TM, Payne SN, Pasch CA, Yueh AE, Van De Hey DR, Korkos DP, Clipson L, Maher ME, Matkowskyj KA, Newton MA, Deming DA.

Mol Cancer Res. 2017 Feb 9;15(3):317-327. doi: 10.1158/1541-7786.MCR-16-0256. [Epub ahead of print]

16.

The effects of tumor treating fields and temozolomide in MGMT expressing and non-expressing patient-derived glioblastoma cells.

Clark PA, Gaal JT, Strebe JK, Pasch CA, Deming DA, Kuo JS, Robins HI.

J Clin Neurosci. 2017 Feb;36:120-124. doi: 10.1016/j.jocn.2016.10.042. Epub 2016 Nov 16.

17.

The Multidisciplinary Management of Colorectal Cancer: Present and Future Paradigms.

Sievers CK, Kratz JD, Zurbriggen LD, LoConte NK, Lubner SJ, Uboha N, Mulkerin D, Matkowskyj KA, Deming DA.

Clin Colon Rectal Surg. 2016 Sep;29(3):232-8. doi: 10.1055/s-0036-1584292. Review.

18.

Molecular Profiles Guide Colorectal Cancer Treatment.

Kratz JD, Turk AA, Sievers CK, Clipson L, Matkowskyj KA, Deming DA.

Fed Pract. 2016 May;33(Suppl 4):50S-53S.

19.

Colon Cancer Tumorigenesis Initiated by the H1047R Mutant PI3K.

Yueh AE, Payne SN, Leystra AA, Van De Hey DR, Foley TM, Pasch CA, Clipson L, Matkowskyj KA, Deming DA.

PLoS One. 2016 Feb 10;11(2):e0148730. doi: 10.1371/journal.pone.0148730. eCollection 2016.

20.

A phase I study of selumetinib (AZD6244/ARRY-142866), a MEK1/2 inhibitor, in combination with cetuximab in refractory solid tumors and KRAS mutant colorectal cancer.

Deming DA, Cavalcante LL, Lubner SJ, Mulkerin DL, LoConte NK, Eickhoff JC, Kolesar JM, Fioravanti S, Greten TF, Compton K, Doyle AG, Wilding G, Duffy A, Liu G.

Invest New Drugs. 2016 Apr;34(2):168-75. doi: 10.1007/s10637-015-0314-7. Epub 2015 Dec 14.

21.

PIK3CA mutations can initiate pancreatic tumorigenesis and are targetable with PI3K inhibitors.

Payne SN, Maher ME, Tran NH, Van De Hey DR, Foley TM, Yueh AE, Leystra AA, Pasch CA, Jeffrey JJ, Clipson L, Matkowskyj KA, Deming DA.

Oncogenesis. 2015 Oct 5;4:e169. doi: 10.1038/oncsis.2015.28.

22.

Precision medicine in colorectal cancer: the molecular profile alters treatment strategies.

Tran NH, Cavalcante LL, Lubner SJ, Mulkerin DL, LoConte NK, Clipson L, Matkowskyj KA, Deming DA.

Ther Adv Med Oncol. 2015 Sep;7(5):252-62. doi: 10.1177/1758834015591952. Review.

23.

Colon Tumors with the Simultaneous Induction of Driver Mutations in APC, KRAS, and PIK3CA Still Progress through the Adenoma-to-carcinoma Sequence.

Hadac JN, Leystra AA, Paul Olson TJ, Maher ME, Payne SN, Yueh AE, Schwartz AR, Albrecht DM, Clipson L, Pasch CA, Matkowskyj KA, Halberg RB, Deming DA.

Cancer Prev Res (Phila). 2015 Oct;8(10):952-61. doi: 10.1158/1940-6207.CAPR-15-0003. Epub 2015 Aug 14.

24.

A multicenter phase 1 study of ╬│ -secretase inhibitor RO4929097 in combination with capecitabine in refractory solid tumors.

LoConte NK, Razak AR, Ivy P, Tevaarwerk A, Leverence R, Kolesar J, Siu L, Lubner SJ, Mulkerin DL, Schelman WR, Deming DA, Holen KD, Carmichael L, Eickhoff J, Liu G.

Invest New Drugs. 2015 Feb;33(1):169-76. doi: 10.1007/s10637-014-0166-6. Epub 2014 Oct 17.

25.

Phospholipid ether analogs for the detection of colorectal tumors.

Deming DA, Maher ME, Leystra AA, Grudzinski JP, Clipson L, Albrecht DM, Washington MK, Matkowskyj KA, Hall LT, Lubner SJ, Weichert JP, Halberg RB.

PLoS One. 2014 Oct 6;9(10):e109668. doi: 10.1371/journal.pone.0109668. eCollection 2014.

26.

Mailed invitations for colorectal screening are effective in increasing screening participation in uninsured adults with faecal immunochemical testing: the preferred screening modality.

LoConte NK, Deming DA.

Evid Based Med. 2014 Aug;19(4):145. doi: 10.1136/eb-2014-101772. Epub 2014 Apr 12. No abstract available.

PMID:
24727711
27.

Dynamic tumor growth patterns in a novel murine model of colorectal cancer.

Paul Olson TJ, Hadac JN, Sievers CK, Leystra AA, Deming DA, Zahm CD, Albrecht DM, Nomura A, Nettekoven LA, Plesh LK, Clipson L, Sullivan R, Newton MA, Schelman WR, Halberg RB.

Cancer Prev Res (Phila). 2014 Jan;7(1):105-13. doi: 10.1158/1940-6207.CAPR-13-0163. Epub 2013 Nov 6.

28.

A Phase I study of intermittently dosed vorinostat in combination with bortezomib in patients with advanced solid tumors.

Deming DA, Ninan J, Bailey HH, Kolesar JM, Eickhoff J, Reid JM, Ames MM, McGovern RM, Alberti D, Marnocha R, Espinoza-Delgado I, Wright J, Wilding G, Schelman WR.

Invest New Drugs. 2014 Apr;32(2):323-9. doi: 10.1007/s10637-013-0035-8. Epub 2013 Oct 10.

29.

Transformation of epithelial cells through recruitment leads to polyclonal intestinal tumors.

Thliveris AT, Schwefel B, Clipson L, Plesh L, Zahm CD, Leystra AA, Washington MK, Sullivan R, Deming DA, Newton MA, Halberg RB.

Proc Natl Acad Sci U S A. 2013 Jul 9;110(28):11523-8. doi: 10.1073/pnas.1303064110. Epub 2013 Jun 24.

30.

PIK3CA and APC mutations are synergistic in the development of intestinal cancers.

Deming DA, Leystra AA, Nettekoven L, Sievers C, Miller D, Middlebrooks M, Clipson L, Albrecht D, Bacher J, Washington MK, Weichert J, Halberg RB.

Oncogene. 2014 Apr 24;33(17):2245-54. doi: 10.1038/onc.2013.167. Epub 2013 May 27.

31.

mTOR inhibition elicits a dramatic response in PI3K-dependent colon cancers.

Deming DA, Leystra AA, Farhoud M, Nettekoven L, Clipson L, Albrecht D, Washington MK, Sullivan R, Weichert JP, Halberg RB.

PLoS One. 2013 Apr 9;8(4):e60709. doi: 10.1371/journal.pone.0060709. Print 2013.

32.

A phase I study of sorafenib, oxaliplatin and 2 days of high dose capecitabine in advanced pancreatic and biliary tract cancer: a Wisconsin oncology network study.

LoConte NK, Holen KD, Schelman WR, Mulkerin DL, Deming DA, Hernan HR, Traynor AM, Goggins T, Groteluschen D, Oettel K, Robinson E, Lubner SJ.

Invest New Drugs. 2013 Aug;31(4):943-8. doi: 10.1007/s10637-012-9916-5. Epub 2012 Dec 21.

33.

Mice expressing activated PI3K rapidly develop advanced colon cancer.

Leystra AA, Deming DA, Zahm CD, Farhoud M, Olson TJ, Hadac JN, Nettekoven LA, Albrecht DM, Clipson L, Sullivan R, Washington MK, Torrealba JR, Weichert JP, Halberg RB.

Cancer Res. 2012 Jun 15;72(12):2931-6. doi: 10.1158/0008-5472.CAN-11-4097. Epub 2012 Apr 23.

34.

Bilateral anterior shoulder dislocation in a young and healthy man without obvious cause.

Bellazzini MA, Deming DA.

Am J Emerg Med. 2007 Jul;25(6):734.e1-3. No abstract available.

PMID:
17606108
35.

A dramatic response to long-acting octreotide in metastatic hepatocellular carcinoma.

Deming DA, Stella AL, Holen KD, Ku G, O'Reilly EM.

Clin Adv Hematol Oncol. 2005 Jun;3(6):468-72; discussion 472-4. No abstract available.

PMID:
16167024

Supplemental Content

Loading ...
Support Center